<p>根據 Candriam S.C.A.最近向證券交易委員會（SEC）提交的 13F 表格，該公司在 2023 年第三季度將其在 Olema Pharmaceuticals, Inc.（NASDAQ:OLMA - 免費報告）的持股比例提高了 46.9%。該機構投資者在此期間額外購買了 399,273 股後，持有該公司 1,249,727 股股票。根據其最近向證券交易委員會（SEC）提交的文件，Candriam S.C.A.持有 Olema Pharmaceuticals 的股份佔比為 1.82%，價值為 12,235,000 美元。</p>
<p>獲取 <strong>Olema Pharmaceuticals</strong> 的提醒：</p>
<p>其他一些對沖基金和機構投資者也對該公司的持倉進行了調整。AQR Capital Management LLC 在第一季度新購入了價值 172,000 美元的 Olema Pharmaceuticals 股票。高盛集團在第一季度將其在 Olema Pharmaceuticals 的持股比例提高了 93.6%。高盛集團目前持有 741,329 股該公司的股票，價值為 2,787,000 美元，此前在此期間又購買了 358,412 股。Jane Street Group LLC 在第一季度將其在 Olema Pharmaceuticals 的持股增加了 216.8%。Jane Street Group LLC 目前持有 138,552 股該公司的股票，價值為 521,000 美元，此前在上個季度又購買了 94,815 股。FNY Investment Advisers LLC 在第二季度將其在 Olema Pharmaceuticals 的持股增加了 100.0%。FNY Investment Advisers LLC 目前持有 10,000 股該公司的股票，價值為 42,000 美元，此前在上個季度又購買了 5,000 股。最後，ProShare Advisors LLC 在第二季度將其在 Olema Pharmaceuticals 的持股提高了 21.1%。ProShare Advisors LLC 目前持有 14,766 股該公司的股票，價值為 63,000 美元，此前在上個季度又購買了 2,569 股。機構投資者和對沖基金持有該公司 91.78% 的股份。</p>
<h2>Olema Pharmaceuticals 股票表現</h2>
<p>週三，OLMA 股票開盤價為 23.37 美元。該股票的 50 日簡單移動平均線為 27.30 美元，200 日簡單移動平均線為 15.91 美元。該公司的流動比率為 8.03，速動比率為 8.03，債務與股本比率為 0.01。Olema Pharmaceuticals, Inc.的 12 個月最低價為 2.86 美元，最高價為 36.26 美元。該公司的市值為 16 億美元，市盈率為-12.50，貝塔值為 1.89。</p>
<p>Olema Pharmaceuticals（NASDAQ:OLMA - 獲取免費報告）最近於 11 月 10 日發佈了季度財報。該公司報告季度每股收益為（0.49 美元），低於市場共識預期的（0.44 美元）0.05 美元。整體來看，股票研究分析師預測 Olema Pharmaceuticals, Inc.在本年度將發佈-2.33 的每股收益。</p>
<h2>華爾街分析師觀點</h2>
<p>OLMA 已成為多份研究報告的主題。高盛集團在 12 月 11 日的研究報告中將 Olema Pharmaceuticals 的目標價從 26.00 美元上調至 38.00 美元，並給予該股票 “買入” 評級。Weiss Ratings 在 1 月 22 日的研究報告中重申了對 Olema Pharmaceuticals 股票的 “賣出（d-）” 評級。Oppenheimer 在 12 月 11 日的研究報告中將 Olema Pharmaceuticals 的目標價從 45.00 美元上調至 48.00 美元，並給予該股票 “跑贏大盤” 評級。HC Wainwright 在 12 月 11 日的報告中將 Olema Pharmaceuticals 的目標價從 36.00 美元上調至 45.00 美元，並給予該公司 “買入” 評級。最後，瑞銀集團在 1 月 7 日的研究報告中開始覆蓋 Olema Pharmaceuticals。他們對該股票設定了 “買入” 評級和 45.00 美元的目標價。八位分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Olema Pharmaceuticals 目前的平均評級為 “適度買入”，平均目標價為 41.00 美元。</p>
<p><strong>查看我們關於 OLMA 的最新報告</strong></p>
<h2>內部人士下注</h2>
<p>在其他新聞中，董事 Cyrus Harmon 於 1 月 20 日星期二出售了 10,000 股該股票，交易平均價格為 26.88 美元，總價值為 268,800.00 美元。交易完成後，該董事持有 727,770 股該公司的股票，價值約為 19,562,457.60 美元。這代表其持股比例減少了 1.36%。該交易已在向 SEC 提交的文件中披露，您可以通過此鏈接訪問。此外，內部人士 Shane William Charles Kovacs 於 1 月 15 日星期四出售了 100,000 股 Olema Pharmaceuticals 股票。該股票的平均售價為 28.73 美元，總交易額為 2,873,000.00 美元。出售後，該內部人士持有 139,727 股該公司的股票，價值約為 4,014,356.71 美元。這代表其持股比例減少了 41.71%。該銷售的 SEC 文件提供了更多信息。內部人士在上個季度出售了 765,501 股公司股票，價值為 22,052,432 美元。16.36% 的股票由內部人士持有。</p>
<h2>Olema Pharmaceuticals 簡介</h2>
<p>（免費報告）</p>
<p>Olema Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，專注於女性癌症的治療方法的發現、開發和商業化。其主要產品候選藥物是 OP-1250，一種雌激素受體（ER）拮抗劑和選擇性 ER 降解劑，目前正在進行針對複發性、局部晚期或轉移性雌激素受體陽性、HER2 陰性乳腺癌的三期臨牀試驗；以及 OP-1250 與 CDK4/6 抑制劑 palbociclib、ribociclib 和 alpelisib 聯合進行的一期/二期臨牀試驗，針對複發性、局部晚期或轉移性雌激素受體陽性、HER2 陰性乳腺癌，同時開發 OPERA-01 用於 ER+/HER2-晚期或轉移性乳腺癌。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，而非 Olema Pharmaceuticals</li>
<li>Nvidia CEO 發出大膽的特斯拉預測</li>
<li>你的銀行賬户不再安全</li>
<li>在 2026 年 5 月之前購買這隻黃金股票</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>黃金市場崩潰的那一天</li>
</ul>
<p><strong>想看看其他對 OLMA 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取 Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - 免費報告) 的最新 13F 文件和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0xNQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0xNQQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Olema Pharmaceuticals 嗎？</h2>
<p>在考慮 Olema Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，而 Olema Pharmaceuticals 並不在名單上。</p>
<p>雖然 Olema Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

OLMA

<p>Candriam S.C.A. 在第三季度將其在 Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) 的持股增加了 46.9%，目前擁有 1,249,727 股，價值 1,224 萬美元。其他機構投資者也調整了他們的持倉，高盛和簡街集團的增持幅度顯著。Olema 的股票開盤價為 23.37 美元，市值為 16 億美元。分析師的評級意見不一，平均目標價共識為 41.00 美元。最近有內部人士出售股票的報告，包括一名董事出售了 10,000 股</p>

<p>Candriam S.C.A. raised its stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 46.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,249,727 shares of the company's stock after acquiring an additional 399,273 shares during the period. Candriam S.C.A. owned 1.82% of Olema Pharmaceuticals worth $12,235,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>根據 Candriam S.C.A.最近向證券交易委員會（SEC）提交的 13F 表格，該公司在 2023 年第三季度將其在 Olema Pharmaceuticals, Inc.（NASDAQ:OLMA - 免費報告）的持股比例提高了 46.9%。該機構投資者在此期間額外購買了 399,273 股後，持有該公司 1,249,727 股股票。根據其最近向證券交易委員會（SEC）提交的文件，Candriam S.C.A.持有 Olema Pharmaceuticals 的股份佔比為 1.82%，價值為 12,235,000 美元。</p>
</div><p>Get <strong>Olema Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Olema Pharmaceuticals</strong> 的提醒：</p>
</div><p>A number of other hedge funds and other institutional investors have also made changes to their positions in the company. AQR Capital Management LLC acquired a new position in shares of Olema Pharmaceuticals in the 1st quarter valued at $172,000. Goldman Sachs Group Inc. grew its stake in shares of Olema Pharmaceuticals by 93.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 741,329 shares of the company's stock worth $2,787,000 after purchasing an additional 358,412 shares during the period. Jane Street Group LLC increased its holdings in Olema Pharmaceuticals by 216.8% in the first quarter. Jane Street Group LLC now owns 138,552 shares of the company's stock valued at $521,000 after buying an additional 94,815 shares in the last quarter. FNY Investment Advisers LLC increased its stake in Olema Pharmaceuticals by 100.0% in the 2nd quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company's stock valued at $42,000 after purchasing an additional 5,000 shares in the last quarter. Finally, ProShare Advisors LLC raised its stake in shares of Olema Pharmaceuticals by 21.1% during the 2nd quarter. ProShare Advisors LLC now owns 14,766 shares of the company's stock worth $63,000 after buying an additional 2,569 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company's stock.</p>
<div class="lb-trans"><p>其他一些對沖基金和機構投資者也對該公司的持倉進行了調整。AQR Capital Management LLC 在第一季度新購入了價值 172,000 美元的 Olema Pharmaceuticals 股票。高盛集團在第一季度將其在 Olema Pharmaceuticals 的持股比例提高了 93.6%。高盛集團目前持有 741,329 股該公司的股票，價值為 2,787,000 美元，此前在此期間又購買了 358,412 股。Jane Street Group LLC 在第一季度將其在 Olema Pharmaceuticals 的持股增加了 216.8%。Jane Street Group LLC 目前持有 138,552 股該公司的股票，價值為 521,000 美元，此前在上個季度又購買了 94,815 股。FNY Investment Advisers LLC 在第二季度將其在 Olema Pharmaceuticals 的持股增加了 100.0%。FNY Investment Advisers LLC 目前持有 10,000 股該公司的股票，價值為 42,000 美元，此前在上個季度又購買了 5,000 股。最後，ProShare Advisors LLC 在第二季度將其在 Olema Pharmaceuticals 的持股提高了 21.1%。ProShare Advisors LLC 目前持有 14,766 股該公司的股票，價值為 63,000 美元，此前在上個季度又購買了 2,569 股。機構投資者和對沖基金持有該公司 91.78% 的股份。</p>
</div><h2>Olema Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Olema Pharmaceuticals 股票表現</h2>
</div><p>OLMA stock opened at $23.37 on Wednesday. The stock's 50 day simple moving average is $27.30 and its 200 day simple moving average is $15.91. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.01. Olema Pharmaceuticals, Inc. has a 12-month low of $2.86 and a 12-month high of $36.26. The firm has a market cap of $1.60 billion, a P/E ratio of -12.50 and a beta of 1.89.</p>
<div class="lb-trans"><p>週三，OLMA 股票開盤價為 23.37 美元。該股票的 50 日簡單移動平均線為 27.30 美元，200 日簡單移動平均線為 15.91 美元。該公司的流動比率為 8.03，速動比率為 8.03，債務與股本比率為 0.01。Olema Pharmaceuticals, Inc.的 12 個月最低價為 2.86 美元，最高價為 36.26 美元。該公司的市值為 16 億美元，市盈率為-12.50，貝塔值為 1.89。</p>
</div><p>Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.05). As a group, equities research analysts predict that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current year.</p>
<div class="lb-trans"><p>Olema Pharmaceuticals（NASDAQ:OLMA - 獲取免費報告）最近於 11 月 10 日發佈了季度財報。該公司報告季度每股收益為（0.49 美元），低於市場共識預期的（0.44 美元）0.05 美元。整體來看，股票研究分析師預測 Olema Pharmaceuticals, Inc.在本年度將發佈-2.33 的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>OLMA has been the subject of several research reports. The Goldman Sachs Group lifted their price objective on Olema Pharmaceuticals from $26.00 to $38.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, December 11th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Olema Pharmaceuticals in a research note on Thursday, January 22nd. Oppenheimer increased their target price on Olema Pharmaceuticals from $45.00 to $48.00 and gave the stock an &#34;outperform&#34; rating in a research report on Thursday, December 11th. HC Wainwright raised their price target on shares of Olema Pharmaceuticals from $36.00 to $45.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, December 11th. Finally, UBS Group initiated coverage on Olema Pharmaceuticals in a research note on Wednesday, January 7th. They set a &#34;buy&#34; rating and a $45.00 price objective on the stock. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Olema Pharmaceuticals currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $41.00.</p>
<div class="lb-trans"><p>OLMA 已成為多份研究報告的主題。高盛集團在 12 月 11 日的研究報告中將 Olema Pharmaceuticals 的目標價從 26.00 美元上調至 38.00 美元，並給予該股票 “買入” 評級。Weiss Ratings 在 1 月 22 日的研究報告中重申了對 Olema Pharmaceuticals 股票的 “賣出（d-）” 評級。Oppenheimer 在 12 月 11 日的研究報告中將 Olema Pharmaceuticals 的目標價從 45.00 美元上調至 48.00 美元，並給予該股票 “跑贏大盤” 評級。HC Wainwright 在 12 月 11 日的報告中將 Olema Pharmaceuticals 的目標價從 36.00 美元上調至 45.00 美元，並給予該公司 “買入” 評級。最後，瑞銀集團在 1 月 7 日的研究報告中開始覆蓋 Olema Pharmaceuticals。他們對該股票設定了 “買入” 評級和 45.00 美元的目標價。八位分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Olema Pharmaceuticals 目前的平均評級為 “適度買入”，平均目標價為 41.00 美元。</p>
</div><p><strong>View Our Latest Report on OLMA</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 OLMA 的最新報告</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other news, Director Cyrus Harmon sold 10,000 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $26.88, for a total value of $268,800.00. Following the completion of the transaction, the director owned 727,770 shares of the company's stock, valued at approximately $19,562,457.60. This represents a 1.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Shane William Charles Kovacs sold 100,000 shares of Olema Pharmaceuticals stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $28.73, for a total transaction of $2,873,000.00. Following the sale, the insider owned 139,727 shares in the company, valued at approximately $4,014,356.71. This represents a 41.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 765,501 shares of company stock valued at $22,052,432 in the last quarter. 16.36% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他新聞中，董事 Cyrus Harmon 於 1 月 20 日星期二出售了 10,000 股該股票，交易平均價格為 26.88 美元，總價值為 268,800.00 美元。交易完成後，該董事持有 727,770 股該公司的股票，價值約為 19,562,457.60 美元。這代表其持股比例減少了 1.36%。該交易已在向 SEC 提交的文件中披露，您可以通過此鏈接訪問。此外，內部人士 Shane William Charles Kovacs 於 1 月 15 日星期四出售了 100,000 股 Olema Pharmaceuticals 股票。該股票的平均售價為 28.73 美元，總交易額為 2,873,000.00 美元。出售後，該內部人士持有 139,727 股該公司的股票，價值約為 4,014,356.71 美元。這代表其持股比例減少了 41.71%。該銷售的 SEC 文件提供了更多信息。內部人士在上個季度出售了 765,501 股公司股票，價值為 22,052,432 美元。16.36% 的股票由內部人士持有。</p>
</div><h2>Olema Pharmaceuticals Profile</h2>
<div class="lb-trans"><h2>Olema Pharmaceuticals 簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.</p>
<div class="lb-trans"><p>Olema Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，專注於女性癌症的治療方法的發現、開發和商業化。其主要產品候選藥物是 OP-1250，一種雌激素受體（ER）拮抗劑和選擇性 ER 降解劑，目前正在進行針對複發性、局部晚期或轉移性雌激素受體陽性、HER2 陰性乳腺癌的三期臨牀試驗；以及 OP-1250 與 CDK4/6 抑制劑 palbociclib、ribociclib 和 alpelisib 聯合進行的一期/二期臨牀試驗，針對複發性、局部晚期或轉移性雌激素受體陽性、HER2 陰性乳腺癌，同時開發 OPERA-01 用於 ER+/HER2-晚期或轉移性乳腺癌。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Olema Pharmaceuticals</li>
<li>Nvidia CEO Issues Bold Tesla Call</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>The day the gold market broke</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而非 Olema Pharmaceuticals</li>
<li>Nvidia CEO 發出大膽的特斯拉預測</li>
<li>你的銀行賬户不再安全</li>
<li>在 2026 年 5 月之前購買這隻黃金股票</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>黃金市場崩潰的那一天</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding OLMA?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 OLMA 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取 Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - 免費報告) 的最新 13F 文件和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0xNQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=OLMA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Olema Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Olema Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Olema Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Olema Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Olema Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，而 Olema Pharmaceuticals 並不在名單上。</p>
</div><p>While Olema Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Olema Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Candriam S.C.A. 增持了 Olema Pharmaceuticals, Inc. 的股票頭寸 $OLMA